Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Lipid modification (Bempedoic acid with ezetimibe - Lipid modification)

Records returned : 20 (on 29 May 2025 at 11:09:37). Return to search results for ' Lipid modification '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Preferred
 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

Important
Only as add-on therapy for patients already on ezetimibe. Use the combination product (bempedoic acid with ezetimibe) in new patients. Specialist team initiation and supply of at least 3 months before transfer of prescribing to primary care.
 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Green
Formulations :
  • Capsules
Restrictions / Comments:

Important
With statin therapy in patients with raised triglycerides
 
Links :
Indication :
Status :
Green
Formulations :
  • Subcutaneous injection (sc)
Restrictions / Comments:

Important
Prescribing in secondary care is commissioned by NHSE - Blueteq forms are required.
 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Green
Formulations :
  • Tablets
Restrictions / Comments:

 
Links :
Indication :
Status :
Blue
Formulations :
  • Modified release tablets
  • Tablets
Restrictions / Comments:

Important
Primary care prescribing on recommendation from specialist team for Familial hypercholesterolaemia and hypertriglyceridaemia.
 
Links :
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important
Primary care prescribing on recommendation from specialist team for Familial hypercholesterolaemia and hypertriglyceridaemia.
 
Links :
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important
Hypercholesterolaemia. Primary care prescribing on specialist team recommendation.
 
Links :
Indication :
Status :
Blue
Formulations :
  • Sachets (powder)
Restrictions / Comments:

Important
Hypercholesterolaemia. Primary care prescribing on specialist team recommendation.
 
Links :
Indication :
Status :
Blue
Formulations :
  • Capsules
  • Tablets
Restrictions / Comments:

Important
Primary care prescribing on recommendation from specialist team for Familial hypercholesterolaemia and hypertriglyceridaemia.
 
Links :
Indication :
Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Restrictions / Comments:

Important
Restricted to lipidologists only.
 
Links :
Indication :
Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Restrictions / Comments:

Important
Restricted to lipidologists only for heterozygous familial and non-familial hypercholesterolaemia.
 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Capsules
  • Tablets
Restrictions / Comments:

Important
Not for initiation in new patients.
 
Links :
Indication :
Status :
See narrative
Formulations :
  • Not Specified
Restrictions / Comments:

Important

This drug has not yet been assessed for formulary status. Contact your pharmacy team for advice on making an application to APC.

 
Links :
20.
Drug:
Indication :
Status :
Restrictions / Comments:

 
Links :